Overview
Ting Lin practices practicing medicine in Changsha, China.
Ms. Lin is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Nasopharyngeal Carcinoma, Anal Cancer, and Oral Squamous Cell Carcinoma.
She is actively involved in clinical research, co-authoring 16 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Ting Lin
Is Ting Lin a top-rated expert for Nasopharyngeal Carcinoma?
MediFind is an objective health platform that identifies experts based on real-world data. Ting Lin is classified as an Advanced expert for Nasopharyngeal Carcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Ting Lin participate in research or clinical trials?
Yes. Ting Lin has published 16 articles and abstracts on conditions like Nasopharyngeal Carcinoma. You can view a list of Ting Lin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Nasopharyngeal CarcinomaMs. Lin isAdvanced. Learn about Nasopharyngeal Carcinoma.
- Experienced
- Anal CancerMs. Lin isExperienced. Learn about Anal Cancer.
- Oral Squamous Cell CarcinomaMs. Lin isExperienced. Learn about Oral Squamous Cell Carcinoma.